Aclipse Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
411 Swedeland Rd Ste 23-1080, King Of Pr...Website
www.aclipsetherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Aclipse Therapeutics
Aclipse Therapeutics specializes in developing innovative therapeutics aimed at treating life-threatening and severe diseases, particularly focusing on neuromuscular conditions. The company utilizes genomic, proteomic, and biomarker data to create disease-modifying drug candidates, with M107 targeting gastroparesis and M102 aimed at amyotrophic lateral sclerosis (ALS). Their approach emphasizes understanding molecular pathways related to inflammation and cellular stress to enhance patient outcomes. Aclipse Therapeutics is transitioning into a clinical stage development company, committed to delivering breakthrough medicines for patients.Explore more
Aclipse Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aclipse Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Aclipse Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Aclipse Therapeutics has new funding data
Check if Aclipse Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Aclipse Therapeutics launches new products
Click to see if Aclipse Therapeutics had a recent Job posting/layoffs
Check out if Aclipse Therapeutics is spiking on competitors!
Aclipse Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Aclipse Therapeutics
Recommended Actions
Reach out to Masked Content who joined Aclipse Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Aclipse Therapeutics
Compare insights from companies similar to Aclipse Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aclipse Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aclipse Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aclipse Therapeutics.
Aclipse Therapeutics Tech Stack
A closer look at the technologies used by Aclipse Therapeutics
See more technologies
Aclipse Therapeutics News & Media
Aclipse Therapeutics Expands Drug Development Pipeline with Signing of Exclusive, Worldwide License Agreement with Chong Kun Dang Pharmaceutical Corporation to Develop Potential Disease-Modifying Treatment for Gastroparesis
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics, and its subsidiary, Aclipse Two, Inc (“Aclipse”), an innovative biopharmaceutical company developing life-changing treatments for patients with severe diseases, announced today that it has signed an exclusive license agreement with Seoul, South Korea-based Chong Kun Dang Pharmaceutical Corporation (“CKD”) for the worldwide rights (excluding South Korea, Indonesia and Vietnam) to develop CKD’s lobeglitazone for gastroparesis and additional indiAclipse Therapeutics Announces $1.475 Million Award from the US Department of Defense
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics Announces $1.475M Award from the U.S. Department of Defense to Support Aclipse's Continued Development of M102 in ALSAclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Development of M102
RADNOR, Pa.--(BUSINESS WIRE)--Aclipse Therapeutics (“Aclipse” or “the Company”), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of £1.6 million (approximately US $2.2 million) from the UK’s Medical Research Council (MRC), one of the largest funders of medical research worldwide, to s
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aclipse Therapeutics
Sign Up For FreeTo access detailed company insights
Aclipse Therapeutics specializes in developing innovative therapeutics aimed at treating life-threatening and severe diseases, particularly focusing on neuromuscular conditions. The company utilizes genomic, proteomic, and biomarker data to create disease-modifying drug candidates, with M107 targeting gastroparesis and M102 aimed at amyotrophic lat... Read More
